All original studies retrieved.

IntroductionTriple semicircular canal plugging is effective in controlling vertigo in patients with Meniere’s disease, however, whether the rate of causing hearing loss during treatment is still not uniform. This study aimed to evaluate the effects of Triple semicircular canal plugging (TSCP) on hearing in Meniere’s disease (MD) patients.MethodsDatabases Reviewed were PubMed, EMBASE, Scopus, Clinical Trials, Web of Science, Cochrane Library, CNKI, Wanfang, and VIP. The study reported on the duration, follow-up time, hearing loss, and vertigo control outcomes in MD patients evaluated by TSCP. Stata 17 software was used for data analysis and assessing the risk of bias.ResultsThis meta-analysis included 367 MD patients from 7 studies. TSCP efficiently alleviated vertigo with a rate of 99% (95% CI: 0.97, 1.00) and had a hearing loss rate of 22% (95% CI: 0.16, 0.28). Subgroup analysis revealed that for hearing loss, the proportion of patients with disease duration more than or less than 12 months was 14% (95% CI: 0.05, 0.26) and 24% (95% CI: 0.19, 0.29), respectively. For vertigo control, the rates were 100% (95% CI: 0.96, 1.00) and 99% (95% CI: 0.97, 1.00), respectively. For hearing loss, the follow-up time of MD patients more than or less than 24 months was 20% (95% CI: 0.07, 0.38) and 23% (95% CI: 0.18, 0.29), respectively. For vertigo control, the rates were 99% (95% CI: 0.95, 1.00) and 99% (95% CI: 0.97, 1.00), respectively. The duration of the disease and follow-up time had no significant impact on hearing loss and vertigo control rates.ConclusionsTSCP was efficient for vertigo control but with a risk of hearing loss. It could be used as a surgical method for hearing preservation in advanced MD patients.**引言**：半规管三重封堵术（Triple semicircular canal plugging, TSCP）对梅尼埃病（Meniere’s disease, MD）患者的眩晕控制效果确切，但术中所致听力损失的发生率目前尚无统一定论。本研究旨在评估半规管三重封堵术（TSCP）对梅尼埃病（MD）患者听力的影响。 **方法**：本研究检索的数据库包括PubMed、EMBASE、Scopus、Clinical Trials、Web of Science、Cochrane图书馆、中国知网（CNKI）、万方数据知识服务平台及维普资讯。纳入经TSCP治疗的MD患者相关研究，提取其病程、随访时长、听力损失情况及眩晕控制结局等数据。采用Stata 17软件进行数据分析及偏倚风险评估。 **结果**：本项荟萃分析（Meta-analysis）共纳入7项研究、367例MD患者。TSCP可有效控制眩晕，控制率达99%（95%置信区间（Confidence Interval, CI）：0.97, 1.00），术中术后听力损失发生率为22%（95%置信区间（Confidence Interval, CI）：0.16, 0.28）。亚组分析显示：按病程是否超过12个月分组时，听力损失发生率分别为14%（95%置信区间（Confidence Interval, CI）：0.05, 0.26）与24%（95%置信区间（Confidence Interval, CI）：0.19, 0.29），对应眩晕控制率则分别为100%（95%置信区间（Confidence Interval, CI）：0.96, 1.00）与99%（95%置信区间（Confidence Interval, CI）：0.97, 1.00）；按随访时长是否超过24个月分组时，听力损失发生率分别为20%（95%置信区间（Confidence Interval, CI）：0.07, 0.38）与23%（95%置信区间（Confidence Interval, CI）：0.18, 0.29），对应眩晕控制率则分别为99%（95%置信区间（Confidence Interval, CI）：0.95, 1.00）与99%（95%置信区间（Confidence Interval, CI）：0.97, 1.00）。病程及随访时长对听力损失发生率与眩晕控制率均无显著影响。 **结论**：TSCP可有效控制梅尼埃病患者的眩晕，但存在引发听力损失的风险，可作为晚期MD患者听力保留的手术方案。